Printer Friendly

Vermillion announces study agreement, coverage with Clalit Health Services.

Vermillion announced a study agreement and coverage with Clalit Health Services in Israel. The study is intended to validate on the local Israeli population: Vermillion's first generation, U.S. FDA cleared, American College of Obstetricians and Gynecologists, or ACOG, recommended ovarian cancer risk assessment test, OVA1, Vermillion's second generation U.S. FDA cleared OVERA test and Vermillion's recently launched OVA1+ which is a reflex process that provides both of these FDA-cleared test results on one informatic report. Clalit Health Services is Israel's largest HMO and healthcare provider, with approximately 3.8M insured members or about half of the insured Israeli population.

COPYRIGHT 2018 The Fly
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:The Fly
Date:Nov 8, 2018
Previous Article:Yelp took steps to alleviate operational issues in Q3.
Next Article:Oasis Petroleum sells select midstream interests to Oasis Midstream Partners.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters